LIFE aTyr Pharma

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results

Management to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020.

Conference Call and Webcast Details:

Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDT

Domestic:  844-358-9116

International:  209-905-5951

Conference ID:  1375605

Webcast:

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit .

Contact: 
Joyce Allaire 
Managing Director, LifeSci Advisors, LLC 
 
  

EN
06/05/2020

Underlying

LIFEaTyr Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on aTyr Pharma

 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr’s common stock, each with an exercise price of $0.98 per share, which is equal...

15m 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma to Present at the Leerink Partners Global Healthcare Confe...

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL. Details of the presentation appear below: Conference: Leeri...

February 18, 2026 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzo...

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Dr...

February 3, 2026 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Confere...

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY. Details of the presentation appears below: Conference:...

November 10, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporat...

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update  Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEG...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch